© 2022 The Oncology Institute of Hope and Innovation. All rights reserved.
The Oncology Institute of Hope and Innovation is a leader in clinical studies, with the goal to advance the treatment of cancer. We conduct more trials than most other community cancer groups in the US. Our research helps us evaluate the effectiveness of treatment, reduce the risk of complications, lower costs and save resources, and continually refine our clinical approach to cancer care.
M14-239
Ph 2 Study of Telisotuzumab Vedotin (ABBV-399) in Previously Treated c-Met+ NSCLC
Request InformationM16-868
Ph 3 Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous NSCLC
Request InformationM20-178
Ph 3 Study of Navitoclax in Combination with Ruxolitinib Versus best available therapy in Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
Request InformationSPI-FOL-102
Ph 1 Study of Pralatrexate in Advanced Solid Tumors or Hematological Malignancies and either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
Request InformationADCT-402-311
Ph 3 Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Request InformationAT148006 (ASPEN-06)
Ph 2/3 Study of ALX148 In Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Request Information20210096 (AMG 552)
Ph 3 Study of Bemarituzumab plus Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b (FORTITUTE-101)
Request Information20210098
Ph 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-102)
Request InformationAB-106-G208
Ph 2 Study of Taletrectinib in Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Request Information8951-CL-5201
Ph 2 Study of Zolbetuximab (IMAB362) in Combination with Nap-Paclitaxel and Gemcitabine (Nab-P+GEM) as 1L Treatment in Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Request InformationD5086C00001
Ph 3 Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma
Request InformationD533BC00001
Ph III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Advanced or Metastatic NSCLC Without Actionable Genomic Alterations with Disease Progression On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
Request InformationD931CC00001
Ph 2 Study of Olaparib versus Olaparib Plus Durvalumab as Neoadjuvant Therapy in BRCA Mutations and Early Stage HER2 - Negative Breast Cancer (OlympiaN)
Request InformationD967UC00001
Ph 3 Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, 1L Metastatic Breast Cancer (DESTINY-Breast09)
Request InformationAVM0703-001
Ph 1/2 Study of AVM0703 (supra-pharmacologic dexamethasone sodium phosphate) in Lymphoid Malignancies
Request InformationBNT000-001
Epidemiological study to determine the prevalence of ctDNA positivity in Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up.
Request InformationBNT122-01
Ph 2 Study of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
Request InformationSS-BSG-001-US
Study of 5 hydroxmethylated cytosine molecular signatures in cell-free DNA in Bladder, Brain, Colorectal, esophageal, gastric, kidney liver, lung (Stage I-II), ovarian, pancreatic, breast, head and neck, endometrial/uterine, and any other solid tumor carcinoma (Excluding prostate and melanoma)
Request InformationBMS CA057-008
Ph 3 Study of CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM)
Request InformationCA116001
Ph 2 Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, versus Investigator’s Choice Chemotherapy in Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Request InformationDS1062-A-U304
Ph 3 Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Advanced or Metastatic PD-L1 High (TPS 50%) NSCLC without Actionable Genomic Alterations (Tropion-LUNG08)
Request InformationDS8201-A-U305
Ph 3 Study of Trastuzumab Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-DM1) in High-Risk HER2-Positive Primary Breast Cancer with Residual Invasive disease in Breast or axillary Lymph nodes following Neoadjuvant Therapy
Request InformationPL3397-A-U401
Long-term study to further evaluate the risk of hepatotoxicity associated with TURALIO™ (pexidartinib) treatment
Request InformationU31402-A-U301
Ph 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFR-mutated NSCLC After Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)
Request InformationDZ2019E0001
Ph 1/2 Study of DZD9008 (EGFR inhibitor) in Advanced NSCLC with EGFR or HER2 mutation
Request InformationAVA-ITP-401 - Marathe
Open Label Study Measuring Safety and Treatment Satisfaction in Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim.
Request InformationDB-1303-O-1001
Ph 1/2a Study of DB-1303 in Advanced/ Metastatic Solid Tumors
Request InformationDB-1305-O-001
Ph 1/2a Study of DB 1305 (ADC of Anti-Trop 2 and a topoisomerase I inhibitor) in Advanced/Metastatic Solid Tumors
Request InformationEF-GP-301
Ph 3 Study of Glufosfamide versus Fluorouracil (5-FU) in Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
Request InformationEMN29
Ph 3 Study of Selinexor, Pomalidomide and Dexamethasone (SPd) versus Elotuzumab, Pomalidomide and Dexamethasone (EloPd) in Relapsed or Refractory Multiple Myeloma (RRMM)
Request InformationEZH-302
Ph 1b/3 Study of Tazemetostat or Placebo in Combination with Lenalidomide plus Rituximab in Relapsed/Refractory Follicular Lymphoma
Request Information4202-HEM-201
Ph 2 Study of FT-4202 in Thalassemia or Sickle Cell Disease.
Request InformationML43171
Ph 3 Study of Giredestrant Plus Everolimus Compared with Exemestane Plus Everolims in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Request InformationGS-US-626-6216
Ph 3 Study of Zimberelimab and Domvanalimab plus Chemotherapy Versus Pembrolizumab plus Chemotherapy for 1L Treatment of Metastatic NSCLC With No EGFR or ALK Genomic Tumor Aberrations
Request InformationGSK 213410
Ph 2/3 Study of Cobolimab+Dostarlimab+Docetaxel versus Dostarlimab+Docetaxel versus Docetaxel alone in advanced NSCLC who have progressed on prior Anti-PD-(L)1 Therapy and Chemotherapy (Costar Lung)
Request Information2018-523-00US1
Ph I Study of HMPL-523 (Syk inhibitor) in Relapsed or Refractory Lymphoma
Request Information2438-301
Ph 1 Study of HBI-2438 (oral KRAS G12C Inhibitor) in Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation
Request InformationHBI-8000-303
Ph 3 Study of HBI-8000 with Nivolumab versus Placebo with Nivolumab in Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors (Pro00056224)
Request Information2385-203
Ph 2 Study of Retifanlimab plus INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as 1L Treatment of PD-L1–Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Request InformationINCB 50465-309
Ph 3 Study of Parsaclisib in Primary Warm Autoimmune Hemolytic Anemia
Request InformationISIS 702843-CS4
Ph 2a Study of ISIS 702843 in Phlebotomy Dependent Polycythemia Vera (PD-PV)
Request InformationA2E-005
Ph 2 study of inupadenant with carboplatin and pemetrexed in non-squamous NSCLC who have progressed on immunotherapy
Request Information61186372PANSC2001
Ph 1/2 Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic NSCLC
Request InformationXPORT-DLBCL-030
A PHASE 2/3, MULTICENTER RANDOMIZED STUDY OF RITUXIMAB-GEMCITABINE-DEXAMETHASONE-PLATINUM (R-GDP) WITH OR WITHOUT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (RR DLBCL)
Request InformationLabCorp Preferred Registry
PRospective rEgistry OF advanced stage cancER (PREFER) patients to assess prevalence of actionable biomarkers and driver mutations using the OmniSeq test and creation of a biobank from community cancer clinics in the United States to address disparities in precision medicine
Request Information20030
Ph 3 Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Request InformationL-02-01
Ph 2 Study of Topically Administered LUT014 (Topical B-Raf Inhibitor) in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions.
Request InformationMCLA-128-CL01
Ph 1/2 Study of MCLA-128, a full length IgGI Bispecific Antibody Targeting HER2 and HER3, in Solid Tumors (eNRGy)
Request InformationMCLA-128-CL03
Ph II Study of Zenocutuzumab (MCLA-128) In Patients with or without Molecularly Defined Cancers
Request Information849-007 (KRYSTAL 7)
Ph 2 Study of MRTX849 (KRAS G12 Inhibitor) in Combination with Pembrolizumab in Advanced NSCLC with KRAS G12C Mutation
Request Information849-012 (KRYSTAL 12)
Ph 3 Study of MRTX849 (KRAS G12 Inhibitor) versus Docetaxel in Previously Treated NSCLC with KRAS G12C Mutation.
Request InformationMOM-M281-006
Study of M281 (Anti-FcRn Antibody) in Warm Autoimmune Hemolytic Anemia
Request InformationMT202
Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Request InformationLLD-001
Photobiomodulation Therapy Using the MuReva Phototherapy System for Oral Mucositis in Head and Neck Cancer Patients Receiving Radiation Therapy with or without Concurrent Chemotherapy
Request InformationI-RUX-15-04
Ph 1 Study of Ruxolitinib, Steroids, and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Request InformationONC-392-001
Ph 1a/1b Study of ONC-392 (Anti-CTLA-4 mAb) Alone and in Combination with Pembrolizumab in Advanced Solid Tumors (Melanoma and NSCLC)
Request InformationCIRM-0001
Ph 1b-2 Study of ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Lymphoid Malignancies
Request InformationOQL011B002
Ph 2 Study of OQL011 (topical VEGFR stimulator) on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Request InformationPRN1008-018
Ph 3 Study of Oral Rilzabrutinib (PRN1008) in Persistent or Chronic Immune Thrombocytopenia (ITP)
Request InformationNEOD001-301
Ph 3 of Birtamimab plus Standard of Care vs. Placebo plus Standard of Care in Mayo Stage IV Light Chain (AL) Amyloidosis
Request InformationR3918-PNH-2021
Ravulizumab controlled Study of Pozelimab and Cemdisrian Combination in Paroxysmal Nocturnal Hemoglobinuria who are Complement Inhibitor Treatment Naive or have not recently received Complement Inhibitor Therapy.
Request InformationWO42633
Ph 3 Study of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine For HER2-Positive Breast Cancer at High Risk Of Recurrence Following Preoperative Therapy.
Request InformationSRK-181-001
Ph 1 Study of SRK-181 (anti-TGFB1) Alone or with a Checkpoint Inhibitor in Locally Advanced or Metastatic Solid Tumors, including Melanoma, Head and Neck Squamous Cell Carcinoma, and NSCLC (DRAGON)
Request InformationSellas SLSG18-301
Open-Label Study of Galinpepimut-S (GPS) Maintenance Monotherapy versus Investigator's Choice of Therapy in Acute Myeloid Leukemia in Complete Remission After 2L Salvage Therapy
Request InformationPEGCET-101
Ph 3 Study Pegcetacoplan in with Cold Agglutinin Disease (CAD)
Request InformationSC104
Ph 2 of SOT101 (IL-5 superagonist) plus Pembrolizumab in Selected Advanced/Refractory Solid Tumors (Prostate, Cutaneous Squamous Cell Carcinoma, NSCLC, HCC, CRC)
Request InformationSPI-GCF-104
Ph 1 Study of Severe Neutropenia After Eflapegrastim Administration in Breast-Cancer Patients Receiving Docetaxel and Cyclophosphamide
Request InformationCLR_15_03 PART C
Ph 1/2 Study of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Request InformationZN-A-1041-101
Ph 1 Study of ZN-A-1041 (HER-2 Inhibitor) Enteric Capsules as a Single Agent or in Combination in HER2-Positive Advanced Solid Tumors
Request Information4020-01-001
Ph 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Advanced Solid Tumors (AMBER)
Request InformationVT3996-202 (NAVAL-1)
Ph 2 Study of Nanatinostat + Valganciclovir in Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
Request InformationVT3996-301
Ph 1b/2 Study of Nanatinostat + Valganciclovir in Advanced Epstein-Barr Virus- Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Recurrent/Metastatic Nasopharyngeal Carcinoma
Request InformationWSTPZ005
Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo for the Prevention of Dose Limiting Chemotherapy Induced Peripheral Neuropathy in Oncology Patients Administered Carboplatin and Paclitaxel
Request Information2020-PT049
Ph 1/2 Study of XB2001 (anti-IL-1⍺ True Human antibody) plus ONIVYDE + 5-Fluorouracil + Leucovorin in advanced pancreatic cancer (1-BETTER)
Request InformationYL-15293-001
Ph 1/2 Study of YL-15293 (KRAS G12C Inhibitor) in Advanced Solid Tumors with a KRAS G12C Mutation
Request InformationZL-1211-001
Ph I/II Study of ZL-1211 (anti-CLDN18.2) in Unresectable or Metastatic Solid Tumors
Request InformationZEN03694-201
Ph 2b Study of ZEN003694 with Enzalutamide versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Request InformationWGI0301-P1U
Ph 3 Study of TRS003 and China-approved Bevacizumab in Combination with Paclitaxel-Carboplatin in Advanced Non-Squamous NSCLC
Request InformationGE-208-401
Study of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions after Progression on 1L Hormonal Therapy
Request Information© 2022 The Oncology Institute of Hope and Innovation. All rights reserved.